NGM tabled its NASH program in 2021 after a key trial failure. Now it’s reporting success in a second study
Bay Area biotech NGM Biopharmaceuticals reported Thursday afternoon that its drug candidate for non-alcoholic steatohepatitis, or NASH, improved results on a liver biomarker blood test in patients with the most severe form of the disease.
But the results come after NGM Bio decided in 2021 against running a pivotal trial for the drug after it failed a mid-stage trial in NASH patients with less advanced forms of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.